Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Array Biopharma

- PMLiVE

Celgene wins US pancreatic cancer indication for Abraxane

Adds to breast cancer and lung cancer indications

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

Otsuka to buy cancer biopharma Astex

Takes control of company behind Dacogen in $886m deal

- PMLiVE

AZ’s olaparib enters phase III for ovarian cancer

Development of the drug had previously been halted in 2011

- PMLiVE

GSK melanoma therapy Tafinlar cleared in EU

Follows approvals for skin cancer drug in US, Canada and Australia

Roche - Basel

Roche wins EU approval for injectable Herceptin

Can reduce cancer drug's administration time from 90 minutes to two minutes

Bayer symbol

EU nod for Bayer’s Stivarga as Nexavar gets US priority review

Advances pharma company’s ambitions in cancer

- PMLiVE

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

- PMLiVE

Lilly buoyant as lung cancer hope clears pivotal study

Necitumumab on course for regulatory submission in 2014

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links